|
Post by agedhippie on Apr 2, 2018 9:13:14 GMT -5
Apple or Google would bring enough funds into play for major national marketing prior to increasing Afrezza sales. Regardless, this remains the longest of long shots. I would like Abbott, maybe Lilly as a partner in the U.S. I don't want ANY company to lock up Afrezza globally as Sanofi proved that to be dangerous. I prefer multiple global deals, i.e. Biomm, as that would allow Mannkind to grow into a major drug company. Maybe Teva in Israel though they usually work with generics. Mike said months ago he wanted partnerships in the U.S. to increase the needed sales force plus he has two international term sheets in hand. This is an exciting time. Based on the history of this company, there will probably be an announcement or two coming out of left field that no one expects. Hurry up!! Apple and Google are not going to get into the drug market any time soon. It's simply not their area of expertise and their shares would get hammered. Abbott is a non-starter, the only drugs they sell are outside the US and are generics (it's a strategic choice). Lilly is a possible. The obstacle is that they already own nearly half the RAA market so do they want to take a drug that would damage their existing cash cow? I think the answer is maybe, but not at a price Mannkind would want. The problem in the RAA insulin market is that it is dominated by two huge players. Nobody is going to want to spend a lot of money buying Mannkind and then having to fight for a market share against two established players unless it can be shown that Mannkind is actively taking meaningful amounts of business away from those two. Without that change a buyer has to ask if they can fair better than Sanofi, already a substantial insulin player, at elbowing into the market. While we all think that Sanofi pulled it punches that is almost certainly not how a buyer would see it - they would see Sanofi deciding it wasn't going to make it and limiting it's losses.
|
|
|
Post by akemp3000 on Apr 2, 2018 9:56:21 GMT -5
A problem with some perspectives is that they're based solely on history. While this is usually predictive, it's not always. Just because Apple, Google, Abbott and others historically wouldn't be interested in Mannkind doesn't mean they won't be looking forward. It certainly can't be stated as fact. Apple and Google for instance have bought companies in the developmental stage with no sales for exorbitant values because they were willing to take a risk that the cutting edge technology would be successful. Just because Afrezza has not lit up sales yet doesn't mean it won't. One expert who likely knows more about the diabetes market and Afrezza than any of us posting herein would be Dr. David Kendall. No doubt during the interview process and his own due diligence, he learned a lot of insider information and obviously came to the conclusion that Afrezza has an excellent chance of becoming the standard of care. There's no reason Apple, Google, Abbott or someone else might not reach the same conclusion. Not saying it's going to happen. Just saying it is a possibility.
|
|